SP
ABBV icon

SWS Partners’s AbbVie ABBV Stock Holding History

SWS Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.36M Sell
13,364
-109,638
-89% -$23.6M 0.73% 44
2026
Q1 		$2.68M Buy
123,002
+111,185
+941% +$24.7M 0.66% 54
2025
Q4 		$2.7M Sell
11,817
-1,180
-9% -$269K 0.65% 55
2025
Q3 		$3.01M Buy
12,997
+420
+3% +$85.5K 0.73% 48
2025
Q2 		$2.33M Sell
12,577
-2,194
-15% -$408K 0.63% 56
2025
Q1 		$3.09M Buy
14,771
+327
+2% +$63.6K 1.02% 30
2024
Q4 		$2.57M Sell
14,444
-35
-0.2% -$6.43K 0.78% 48
2024
Q3 		$2.86M Sell
14,479
-2,123
-13% -$396K 0.91% 32
2024
Q2 		$2.84M Buy
16,602
+356
+2% +$59K 0.85% 38
2024
Q1 		$2.96M Sell
16,246
-824
-5% -$142K 0.88% 39
2023
Q4 		$2.65M Sell
17,070
-318
-2% -$46.4K 0.86% 41
2023
Q3 		$2.59M Sell
17,388
-2,664
-13% -$391K 0.96% 39
2023
Q2 		$2.7M Buy
20,052
+2,815
+16% +$413K 0.97% 37
2023
Q1 		$2.75M Sell
17,237
-648
-4% -$99.1K 1.02% 28
2022
Q4 		$2.89M Buy
17,885
+1,359
+8% +$208K 1.37% 21
2022
Q3 		$2.22M Buy
16,526
+161
+1% +$23.1K 1.03% 36
2022
Q2 		$2.51M Sell
16,365
-2,028
-11% -$310K 2.11% 8
2022
Q1 		$2.98M Sell
18,393
-2,008
-10% -$292K 1.95% 11
2021
Q4 		$2.76M Sell
20,401
-978
-5% -$116K 1.57% 20
2021
Q3 		$2.31M Sell
21,379
-12,430
-37% -$1.42M 1.43% 23
2021
Q2 		$3.81M Buy
33,809
+2,160
+7% +$243K 2.48% 5
2021
Q1 		$3.42M Buy
31,649
+3,832
+14% +$410K 2.36% 6
2020
Q4 		$2.98M Buy
27,817
+790
+3% +$75.9K 1.33% 16
2020
Q3 		$2.37M Buy
27,027
+9,932
+58% +$935K 1.19% 25
2020
Q2 		$1.62M Sell
17,095
-2,822
-14% -$248K 2.07% 9
2020
Q1 		$1.52M Buy
+19,917
New +$1.7M 1.09% 24
2018
Q4 		$1.84M Sell
19,934
-7,179
-26% -$631K 1.39% 21
2018
Q3 		$2.56M Buy
27,113
+5,588
+26% +$530K 1.63% 23
2018
Q2 		$1.99M Buy
21,525
+2,658
+14% +$260K 1.4% 27
2018
Q1 		$1.73M Buy
18,867
+295
+2% +$32.4K 1.27% 24
2017
Q4 		$1.8M Buy
+18,572
New +$1.75M 1.35% 23

Other funds holding ABBV

Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

SWS Partners's ABBV Position: Q2 2026 in Review

SWS Partners reduced its AbbVie (ABBV) stake by 89% in Q2 2026, selling an estimated $23.6M and leaving 13,364 shares worth $3.36M. The position accounts for 0.73% of the portfolio, ranked #44.

SWS Partners first reported a position in ABBV in Q4 2017 and has held it in 31 quarters since. The position peaked at $3.81M in Q2 2021. 2,236 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • SWS Partners held 13,364 shares of AbbVie worth $3.36M as of Q2 2026.
  • SWS Partners sold 109,638 AbbVie shares in Q2 2026, an estimated $23.6M.
  • AbbVie made up 0.73% of SWS Partners's portfolio in Q2 2026, its #44 holding.
  • SWS Partners first reported a position in AbbVie in Q4 2017 and has held it in 31 quarters since.
  • SWS Partners's AbbVie position peaked at $3.81M in Q2 2021.
  • 2,236 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on SWS Partners's 13F filing for Q2 2026, filed 3 Aug 2026.